From the Food and Drug Administration.
Henney
J E
JE
D011125:Adenomatous Polyposis Coli / Q000188:drug therapy*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077610:Bexarotene; D000068579:Celecoxib; D020117:Cisapride; D000075202:Contraindications; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004348:Drug Labeling; D005765:Gastrointestinal Agents; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D011720:Pyrazoles; D018168:Receptors, Retinoic Acid / Q000187:drug effects*; D013449:Sulfonamides / Q000627:therapeutic use*; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D005765:Gastrointestinal Agents; D011720:Pyrazoles; D018168:Receptors, Retinoic Acid; D013449:Sulfonamides; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene; D000068579:Celecoxib; D020117:Cisapride